Medical devices, healthcare technology and the business of care
510(k) clearance · K260416

ZYLOX Hippo PTA Balloon Dilatation Catheter

Zylox Medtech Co., Ltd. · Decision date Sep 21, 2026

MEDTECHLEDGER EXPLANATIONK260416

What did the FDA decide?

The FDA recorded a decision of SESE for application K260416, titled ZYLOX Hippo PTA Balloon Dilatation Catheter, dated 2026-09-21. The applicant is Zylox Medtech Co., Ltd., the specialty is listed as Cardiovascular, and the product code is LIT. In 510(k) practice, SESE denotes a substantially equivalent determination, meaning clearance rather than premarket approval of a new device.

The available excerpt from the decision letter states that the catheter is also indicated for post-dilatation of stents and stent grafts in the peripheral vasculature. The excerpt does not identify a predicate device, the specific component or modification under review, or the full indications cleared, so those details remain unknown from this record. The letter also notes that some cleared products may be combination products rather than devices.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Cardiovascular
Decision date
Sep 21, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K260416
Regulatory pathway
510(k) premarket notification
Product code
LIT
Decision code
SESE
Decision date
Sep 21, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Catheter, Angioplasty, Peripheral, Transluminal.

Product code
LIT
FDA device class
2

FDA decision timeline

  1. K260416 received

    Application receipt date recorded by FDA.

  2. K260416 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code LIT

Product / regulatory recordCompanyPathwayDecision dateSource
Brosmed Medical Co., Ltd.510(k) clearanceNov 2, 2026FDA
Kossel Medtech (Suzhou) Co., Ltd.510(k) clearanceSep 16, 2026FDA
WAVE Medical AG510(k) clearanceMay 20, 2026FDA
ABBOTT MEDICAL510(k) clearanceFeb 13, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Zylox Medtech Co., Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Hangzhou

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records